• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吉西他滨诱导的胰腺癌溶血尿毒综合征：病例报告及文献复习。

Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.

机构信息

Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Gut Liver. 2014 Jan;8(1):109-12. doi: 10.5009/gnl.2014.8.1.109. Epub 2014 Jan 13.

DOI:10.5009/gnl.2014.8.1.109
PMID:24516709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3916680/
Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

摘要

溶血尿毒综合征（HUS）是一种罕见的血栓性并发症，其特征为微血管性溶血性贫血、血小板减少症和急性肾衰竭三联征。HUS 可能由多种不同的情况引起，包括感染、恶性肿瘤和化疗药物，如丝裂霉素、顺铂，以及最近的吉西他滨。吉西他滨引起的 HUS 预后较差，且该病死亡率较高。本研究报告了韩国 1 例胰腺癌患者吉西他滨诱导的 HUS 病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/062d/3916680/b392f3eb6c07/gnl-8-109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/062d/3916680/57c22e6381ca/gnl-8-109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/062d/3916680/b392f3eb6c07/gnl-8-109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/062d/3916680/57c22e6381ca/gnl-8-109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/062d/3916680/b392f3eb6c07/gnl-8-109-g002.jpg

相似文献

1
Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.吉西他滨诱导的胰腺癌溶血尿毒综合征：病例报告及文献复习。
Gut Liver. 2014 Jan;8(1):109-12. doi: 10.5009/gnl.2014.8.1.109. Epub 2014 Jan 13.
2
Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.吉西他滨相关的溶血尿毒综合征：一例病例报告及文献复习
JOP. 2005 Jul 8;6(4):369-74.
3
[Hemolytic uremic syndrome following gemcitabine treatment].
Rev Med Suisse. 2008 Apr 23;4(154):1056-61.
4
Chronic anemia resistant to erythropoietin in a patient treated with gemcitabine showing a hemolytic uremic syndrome (HUS).
Gastroenterol Clin Biol. 2010 Nov;34(11):640-2. doi: 10.1016/j.gcb.2010.07.020.
5
Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
Cancer Chemother Pharmacol. 2017 Jan;79(1):1-7. doi: 10.1007/s00280-016-3123-6. Epub 2016 Aug 6.
6
[Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
Rev Med Chil. 2013 Jun;141(6):797-802. doi: 10.4067/S0034-98872013000600016.
7
[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].[1例胰腺癌患者吉西他滨辅助化疗后发生溶血性尿毒症综合征]
Nihon Shokakibyo Gakkai Zasshi. 2010 Oct;107(10):1676-85.
8
Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.吉西他滨诱导的溶血尿毒综合征采用依库珠单抗或血浆置换治疗：两例病例报告
Clin Nephrol. 2017 Feb;87 (2017)(2):100-106. doi: 10.5414/CN108838.
9
Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.一名患有胆管癌的年轻女性因吉西他滨导致溶血性尿毒症综合征。
J Bras Nefrol. 2016 Jun;38(2):255-9. doi: 10.5935/0101-2800.20160035.
10
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Rev Med Interne. 2005 Mar;26(3):179-88. doi: 10.1016/j.revmed.2004.11.016. Epub 2005 Jan 11.

引用本文的文献

1
Nephrotic Syndrome and Posterior Reversible Encephalopathy Syndrome as Clinical Presentations of Gemcitabine-Induced Thrombotic Micro-Angiopathy.吉西他滨诱导的血栓性微血管病的临床表现为肾病综合征和后部可逆性脑病综合征
Indian J Nephrol. 2024 Jan-Feb;34(1):74-78. doi: 10.4103/ijn.ijn_277_22. Epub 2023 Mar 7.
2
Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome.依库珠单抗治疗吉西他滨诱导的非典型溶血性尿毒症综合征。
Cureus. 2023 Mar 7;15(3):e35874. doi: 10.7759/cureus.35874. eCollection 2023 Mar.
3
The Nephrotoxicity of Drugs Used in Causal Oncological Therapies.

本文引用的文献

1
Gemcitabine induced hemolytic uremic syndrome.吉西他滨诱发溶血尿毒综合征。
Am J Case Rep. 2012;13:89-91. doi: 10.12659/AJCR.882858. Epub 2012 May 25.
2
Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.多柔比星脂质体注射液联合吉西他滨治疗转移性乳腺癌的Ⅱ期临床试验。
Am J Clin Oncol. 2012 Feb;35(1):18-21. doi: 10.1097/COC.0b013e3182005783.
3
[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
用于因果性肿瘤治疗的药物的肾毒性。
Curr Oncol. 2022 Dec 8;29(12):9681-9694. doi: 10.3390/curroncol29120760.
4
Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.造血作用和血液学药物毒性中的溶质载体核苷转运体：一种观点
Cancers (Basel). 2022 Jun 25;14(13):3113. doi: 10.3390/cancers14133113.
5
A rare case report of gemcitabine-induced thrombotic microangiopathies.吉西他滨诱导的血栓性微血管病的罕见病例报告。
SAGE Open Med Case Rep. 2021 May 24;9:2050313X211013208. doi: 10.1177/2050313X211013208. eCollection 2021.
6
Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome.关于非典型溶血性尿毒症综合征的诊断和治疗的共识。
Korean J Intern Med. 2020 Jan;35(1):25-40. doi: 10.3904/kjim.2019.388. Epub 2020 Jan 2.
7
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.吉西他滨诱导的胰腺腺癌溶血性尿毒症综合征
BMJ Case Rep. 2019 Apr 8;12(4):e228363. doi: 10.1136/bcr-2018-228363.
8
Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.新型组蛋白去乙酰化酶抑制剂CUDC-101联合吉西他滨在胰腺癌中的抗肿瘤活性
Am J Cancer Res. 2018 Dec 1;8(12):2402-2418. eCollection 2018.
9
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.与吉西他滨使用相关的血栓性微血管病：法国全国回顾性队列研究中的表现和结局。
Br J Clin Pharmacol. 2019 Feb;85(2):403-412. doi: 10.1111/bcp.13808. Epub 2018 Dec 18.
10
Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.吉西他滨诱导的血栓性微血管病伴肾病综合征。
CEN Case Rep. 2018 Nov;7(2):217-220. doi: 10.1007/s13730-018-0332-3. Epub 2018 May 15.
[1例胰腺癌患者吉西他滨辅助化疗后发生溶血性尿毒症综合征]
Nihon Shokakibyo Gakkai Zasshi. 2010 Oct;107(10):1676-85.
4
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?对于吉西他滨诱导的溶血性尿毒症综合征患者，治疗性血浆置换是否适用？
J Clin Apher. 2009;24(5):209-14. doi: 10.1002/jca.20213.
5
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.吉西他滨肾毒性与溶血尿毒综合征：来自单一机构的29例报告。
Clin Nephrol. 2009 Feb;71(2):130-9. doi: 10.5414/cnp71130.
6
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.利妥昔单抗治疗转移性胰腺腺癌患者吉西他滨诱导的溶血尿毒综合征：一例报告
Cancer Chemother Pharmacol. 2009 Jun;64(1):177-81. doi: 10.1007/s00280-008-0900-x. Epub 2008 Dec 31.
7
Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer.
J Clin Gastroenterol. 2008 May-Jun;42(5):551-2. doi: 10.1097/MCG.0b013e31802da22e.
8
Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine.单次使用吉西他滨后发生血栓性血小板减少性紫癜
Ann Hematol. 2008 Jun;87(6):495-6. doi: 10.1007/s00277-007-0429-9. Epub 2007 Dec 21.
9
Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.吉西他滨相关的溶血尿毒综合征：一例病例报告及文献复习
JOP. 2005 Jul 8;6(4):369-74.
10
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.三例卵巢癌患者在接受吉西他滨与聚乙二醇化脂质体阿霉素联合治疗后发生溶血尿毒综合征。
Gynecol Oncol. 2005 Apr;97(1):228-33. doi: 10.1016/j.ygyno.2004.12.027.